Fresenius Kabi USA LLC - Company Profile
Powered by 
All the sales intelligence you need on Fresenius Kabi USA LLC in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Fresenius Kabi USA LLC fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Fresenius Kabi USA LLC.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Fresenius Kabi USA LLC (Fresenius Kabi), a subsidiary of Fresenius Kabi AG, is a pharmaceutical and medical device company that provides medicines and technologies for infusion, transfusion and clinical nutrition. It provides products and services to critically and chronically ill patients. The company offers injectable drugs and delivery systems, advanced transfusion medicine, cell therapy, infusion, and clinical nutrition technologies. Its products are categorised into five divisions includes Pharma, Biopharma, Nutrition, and MedTech. Its products include oncology, anesthesia, analgesia, anti-infectives, parenteral nutrition, iv solutions, and other critical care therapies. The company caters its products to hospitals, long-term care facilities, alternate care sites and clinics. It has a presence in Canada and operates manufacturing and distribution units in Illinois, New York, Pennsylvania, Puerto Rico, the Dominican Republic, Mississippi, and California. Fresenius Kabi is headquartered in Lake Zurich, Illinois, the US.
Headquarters
United States of America
Address
3 Corporate Drive, Lake Zurich, Illinois, 60047
Website
www.fresenius-kabi.com
Telephone
1 847 5502300
No of Employees
2,500
Industry
Pharmaceuticals and Healthcare
Fresenius Kabi USA LLC premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Anesthesia & Analgesia | Diprivan |
| Anti-Infectives | Nebupent |
| Oncology | Simplist |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In December, the company launched Denosumab Biosimilars Conexxence1 (denosumab) and Bomyntra2 (denosumab). |
| 2025 | Contracts/Agreements | In August, the company entered into an agreement with Polpharma Biologics to commercialize a proposed Vedolizumab Biosimilar. |
| 2025 | Regulatory Approval | In July, the company received approval from European Commission for Denosumab Biosimilars. |
Competitor Comparison
| Key Parameters | Fresenius Kabi USA LLC | Terumo Corp | Amphastar Pharmaceuticals Inc | Allergan Ltd | Baxter Laboratories Pty Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | Japan | United States of America | Ireland | Australia |
| City | Lake Zurich | Shibuya-Ku | Rancho Cucamonga | Dublin | Boronia |
| State/Province | Illinois | Tokyo | California | Leinster | Victoria |
| No. of Employees | 2,500 | 30,689 | 2,028 | - | - |
| Entity Type | Private | Public | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pierluigi Antonelli | President; Chief Executive Officer | Senior Management | 2023 | - |
| Andreas Duenkel | Chief Financial Officer | Senior Management | 2022 | - |
| Tanja Bender | Chief Human Resources Officer | Senior Management | - | - |
| Arunesh Verma | President | Senior Management | 2024 | - |
| Alain Mollard | Executive Vice President - Region International | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer